论文部分内容阅读
目的探讨腹膜播散型胃癌姑息性胃切除后腹腔化疗的价值。方法２１例腹膜播散型胃癌姑息性胃切除后腹腔内５ＦＵ１ｇ化疗，每天一次连用５天为１疗程，每月重复，６个疗程后结束化疗。并与１５例腹膜播散型胃癌姑息性胃切除后静脉化疗相比较。结果腹腔化疗组无明显毒副反应，术后一年、二年的生存率分别为８０７％、４７１％，对照组生存率为５６５％、１４３％。治疗组的一年、二年生存率明显高于对照组（Ｐ＜００１）。结论腹腔化疗毒副反应少，是腹膜播散胃癌姑息性胃切除后较好的辅助治疗措施。
Objective To investigate the value of intraperitoneal chemotherapy after palliative gastrectomy for peritoneal disseminated gastric cancer. METHODS: In 21 cases of peritoneal disseminated gastric cancer after palliative gastrectomy, intraperitoneal 5-FU1g chemotherapy was used once a day for 5 days as a course of treatment, repeated monthly, and chemotherapy was terminated after 6 cycles. And compared with 15 cases of peritoneal disseminated gastric cancer after palliative gastrectomy compared with intravenous chemotherapy. RESULTS: There were no obvious toxic and side effects in the intraperitoneal chemotherapy group. The one-year and two-year survival rates were 80.7% and 47.1%, respectively. The survival rates in the control group were 56.5% and 14.4%, respectively. The one-year and two-year survival rates of the treatment group were significantly higher than those of the control group (P<001). Conclusion Intraperitoneal chemotherapy has fewer side effects and is a good adjuvant treatment for peritoneal disseminated gastric cancer after palliative gastrectomy.